Gilgamesh Pharma is revolutionizing the treatment paradigm for depression, anxiety, drug addiction, and other debilitating mental illnesses. With a mission to address the pressing unmet needs in patients, they are developing novel compounds that capture the therapeutic benefits of psychedelics. What sets Gilgamesh apart is their AI-powered behavioral and imaging driven platform.

This cutting-edge technology accelerates and optimizes the development of their new chemical entities (NCEs). These compounds offer improved safety, tolerability, duration, and efficacy compared to available psychiatric medicines. The platform utilizes complex behavioral assessment, advanced electrophysiology, and molecular measures of neuroplasticity to identify and classify novel psychoactive drugs.

Machine learning algorithms are employed to systematically characterize the multidimensional bioactivity of known and novel psychoactive molecules, enhancing clinical translation. Supported by notable investors like Y Combinator and Prime Movers Lab, Gilgamesh Pharma is at the forefront of reshaping the treatment of mental illness. Visit their website to learn more about partnerships, investment opportunities, and careers in this groundbreaking field